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Background: There is controversy regarding the choice of prosthetic valves in patients with cardiac valve disease
and dialysis-dependent patients. This review assesses a 12-year experience and outcomes after valve replacement in
patients on chronic preoperative renal dialysis, comparing survival and valve-related outcomes following valve
replacement with bioprostheses versus mechanical prostheses in this population in china.
Methods: From January 1999 and October 2011, 73 consecutive dialysis patients underwent cardiac valve
replacement. The patients were divided into two groups: (Group B) bioprosthesis valves were implanted in 38
(52.1%) patients and (Group M) mechanical valves were implanted in 35 (47.9%) patients. Outcome measures
included perioperative data, hospital mortality, major postoperative complications, follow-up outcomes, valve
related morbidity and late survival.
Results: There were no significant differences in terms of patient characteristics in the 2 groups. Thirty-three were
isolated aortic valve replacements (45.2%); 28 were isolated mitral valve replacements (38.4%); 10 were combined
aortic and mitral replacements (13.7%); 2 were combined tricuspid and mitral replacements (2.7%). The overall
hospital mortality was 5.5% (n = 4) and was not different between Group B (5.3%) and Group M (5.7%). Low
ejection fraction was the only independent predictors of hospital mortality. There was no significant difference
between the groups in the overall rate of complications. The overall mean follow-up was 47 ± 23 months.
According to the Kaplan-Meier analysis, late mortality, perivalvular leak and freedom from reoperation were similar
in patients with mechanical and bioprosthesis valves. The bioprosthesis valve group had significantly higher
freedom from thromboembelism-bleeding events (100% versus 77.6 ± 11.0%, p = 0.012), and valve-related morbidity
(73.2 ± 10.1% versus 58.1 ± 10.9%, p = 0.035) in 5 years. Kaplan–Meier survival estimates at 1, 3, and 5 years were
0.971, 0.832, and 0.530 in group B, and 0.967, 0.848, and 0.568 in group M.
Conclusions: There is no significant difference in the perioperative morbidity and mortality, late survival of dialysis
patients after cardiac valve replacement with bioprostheses versus mechanical valves. In spite of the limited sample
size analyzed, its outcome and consistency to several previous reports supports a conclusion that bioprostheses
rather than mechanical ones could be a favorable choice for valve replacement needs of renal failure patients.Background
Chronic kidney disease population is increasing, so is
the dialysis population. Cardiac disease is a major cause
of death in patients with end-stage renal disease (ESRD)
on hemodialysis [1]. Only 1.5 deaths/1000 patient-years
were ascribed to valvular heart disease [2]. Most sur-
geons believe that mechanical valves are superior to
bioprosthetic valves in the setting of chronic renal* Correspondence: stevecx1@163.com
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reproduction in any medium, provided the orfailure, because of accelerated bioprosthesis calcification
and structural degeneration [3,4]. Controversy persists
with regard to the optimum choice of prosthesis for
valve replacement in dialysis-dependent patients [5,6].
However, the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for valve re-
placement recommend the use of mechanical valves in
dialysis-dependent patients [7].
Given the poor long-term survival of dialysis patients,
we reasoned that patients receiving bioprosthese may die
before valve failure occur. More recent literature chal-
lenges this notion based on the increased risk of strokel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy [8,9]. The purpose of our investigation was,
therefore, to analyze our experience with valve replace-
ment in patients on dialysis in order to formulate guide-
line for choice of valve prostheses.
Methods
Patients
The study protocol was approved by the institutional
review committee of the Nanjing First Hospital, and in-
formed consent was obtained from all patients.
Seventy-three patients requiring chronic hemodialysis
underwent valve replacement at Nanjing First Hospital
affiliated Nanjing Medical University between January
1999 and October 2011. Patients with acute renal fail-
ure, not on chronic hemodialysis, were excluded from
this review. Patients who required concomitant coron-
ary artery bypass grafting (CABG) or re-operative sur-
gery were not included in the study.
Mean age was 56.8 ± 14.3 years (range, 28 to 75).
Bioprostheses and mechanical prostheses populations
were compared through analysis of preoperative vari-
ables listed in Table 1.
The decision regarding type of valve placed was made







Age (y) 55 ± 8 53 ± 9 NS
Female sex 16 (42.1%) 15(42.9%) NS
Mean body mass index (kg/m2) 24 ± 5 26 ± 6 NS
Risk factors
Hypertension 34(89.5%) 32(91.4%) NS
Diabetes 15(39.5%) 12(34.3%) NS
Obstructive pulmonary disease 4(10.5%) 3(8.6%) NS
Previous gastrointestinal bleed 7(18.4%) 6(17.1%) NS
Peripheral vascular disease 3(7.9%) 2(5.7%) NS
Mean preoperative creatinine (mg/dl) 4.5 ± 1.2 4.8 ± 1.4 NS
Cardiac profile
Previous myocardial infarction 2(5.3%) 2(5.7%) NS
Previous PCI 5(13.2%) 4(11.4%) NS
Cardiac arrhythmia 27(71.1%) 31(88.6%) <0.05
Congestive heart failure (NYHA III-IV) 12(31.6%) 11(31.4%) NS
Mean ejection fraction 0.50 ± 0.12 0.49 ± 0.14 NS
Poor ejection fraction (<0.35) 4(10.5%) 4(11.4%) NS
Preoperative endocarditis 6(15.8%) 5(14.3%) NS
Mean EuroSCORE (%) 32 ± 23 31 ± 22 NS
Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant.patient. In general, patients who received a mechanical
valve were deemed to have a probable survival greater
than 5 years. Those with expected survivals less than 5
years were considered primarily bioprosthetic candi-
dates. Other factors such as an inability to tolerate war-
farin anticoagulation and individual surgeon’s experience
also affected valve selection.
In hemodialysis patients, valve replacement with a
mechanical prosthesis is classified as group M, and valve
replacement with a bioprosthesis is classified as group B.
There were 38 bioprostheses replacements and 35 mech-
anical prostheses replacements.
Surgical management
All procedures were performed through a full me-
dian sternotomy. Cardiopulmonary bypass(CPB) was
established between the ascending aorta and either
the right atrium using a two-stage cannula or both
venae cavae, and myocardial protection was achieved
using high potassium cold blood cardioplegia in an
antegrade fashion. During CPB, a perfusion pressure
of >60 mmHg and a minimum flow of 2.2 l/min/m2
were maintained in all patients. Following surgery, all
patients were transferred to the intensive care unit
(ICU). Patients were weaned from ventilator when
haemodynamic stability was achieved, no postopera-
tive bleeding occurred and adequate consciousness
was obtained.
All patients received routine hemodialysis on the day
before the operation. Only hemofiltration was conducted
during CPB. At the end of CPB, the serum potassium
level was < 4.0 mEq · L-1. Hemodialysis resumed on the 1st
postoperative day. If the patient was hemodynamically un-
stable, continuous hemofiltration was applied.
Discharge anticoagulation management
Patients with a mechanical valve were managed with
warfarin therapy. Those who had a bioprostheses were
also given warfarin for the first 3 months after surgery.
Warfarin therapy was started generally on the 2nd post-
operative day. No antiplatelet drugs were used for either
type of valve. Warfarin was adjusted to maintain an INR
of 1.8 to 2.5 after all valve replacements.
Follow-up
The mean follow-up period was 47 ± 23 months (range,
2–88 months). Late complications were documented
wherever possible without bias to the type of valve sub-
stitute implanted. Comparison of outcomes between
Groups M and B was performed, followed by an analysis
of outcome by type and site of valve prosthesis with par-
ticular regard to long-term survival.
Specific endpoints are recorded for reporting morbid-
ity and mortality after cardiac valvular operations and
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thrombosis, structural valve failure, reoperation, pros-
thetic valve endocarditis (PVE), peravalvular leak and
bleeding events. Information obtained from a computer-
based valve replacement database, telephone interviews
and patient charts was reviewed for follow up data.
Statistical analysis
Continuous data are presented as the range and, in
parentheses, the mean ± standard deviation. Survival
estimates were calculated using the Kaplan-Meier
method. Actuarial curves were constructed to describe
mortality and the incidence of valve-related complica-
tions using the Kaplan-Meier technique, and differ-
ences between the two groups were compared with
the log rank test. A P-value <0.05 was considered sta-
tistically significant for all used tests. The statistical
analyses were performed with the use of SPSS 15
(SPSS Inc., Chicago, IL, USA). Stepwise multivariate
logistic regression was then performed to assess the




There were no significant differences between group M
and B in terms of patient characteristics, preoperative
risk factors, or cardiac profiles (Table 1).
Intraoperative data
Thirty-five mechanical valves (47.9%) and 38 bioprosthesis
valves (52.1%) were implanted. Thirty-three were isolated
aortic valve replacements (45.2%); 28 were isolated mitral
valve replacements (38.4%); 10 were combined aortic and
mitral replacements (13.7%); 2 were combined tricuspid
and mitral replacements (2.7%).
There were no differences in terms of CPB and cross-
clamp times between the two groups. There was no sig-
nificant difference in the type of prosthesis implanted






Cross-clamp time (min) 98 ± 21 101 ± 22 NS
Cardiopulmonary bypass time (min) 132 ± 30 136 ± 33 NS
Operative time (min) 213 ± 42 210 ± 48 NS
Aortic valve replacement 18(47.4%) 15(42.9%) NS
Mitral valve replacement 15(39.5%) 13(37.1%) NS
Aortic + mitral valve replacement 4(10.5%) 5(14.3%) 0.035
Tricuspid + mitral valve replacement 1(2.6%) 1(2.9%) NS
Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant.Mortality
The overall hospital mortality was 5.5% (n = 4). Hospital
mortality was 5.7% (2/35) for mechanical valves, and
5.3% (2/38) for bioprothesis valves. Among the mechan-
ical valve recipients, one died from sepsis and one from
pericardial tamponade. Among the bioprothesis valve re-
cipients, one died from mesenteric ischemia and another
from hemorrhage during a separate, non-cardiac-related
operation.
The univariate predictors of composites of hospital
mortality are listed in Table 3. The only significant
multivariate independent predictors of hospital mortality
was low ejection fraction (<35%) (OR = 3.32, p<0.05).
Morbidity
Postoperative complications are shown in Table 4.
There was no significant difference between the groups
in the overall rate of complications. In-hospital postop-
erative complications include bleeding requiring explor-
ation in 4; respiratory failure in 4; heart block requiring
permanent pacemaker placement in 2; sepsis in 2; myo-
cardial infarction in 2; and pericarditis with effusion
and tamponade requiring open pericardial fenestration
in 2 patients. The overall rate of reoperation for bleed-
ing was 5.4% and not significantly different between the
groups. Patients of Group M, however, presented sig-
nificantly more often with Gastrointestinal complica-
tions (P<0.05). Finally, the median length of ICU stay
among patients of Groups B and M was 3.5 ± 1.0 and
3.6 ± 1.2 days, respectively.
Late-term outcomes
Follow-up was completed for all survival patients. The
overall mean follow-up was 47 ± 23 months. There were
10 (14.5%) deaths during the total follow-up of 69 pa-
tients who survived to hospital discharge, with late mor-
tality of 19.4% in group B and 21.2% in group M. When
patients were compared, thrombotic and bleeding events
(Figure 1; Table 5), and valve-related morbidity were sig-
nificantly higher in the mechanical group (Figure 2;
Table 5). Kaplan-Meier freedom from mortality (Figure 3;
Table 5), PVE (Table 5) and perivalvular leak (Table 5)Table 3 Predictors of hospital mortality in multivariate
analysis
Odds ratio C.I.95% P-value
Ejection fraction < 30% 3.32 1.19–8.95 0.021
Peripheral vascular disease 2.12 1.13–8.22 0.26
Aortic valve replacement 3.18 1.28–9.06 0.13
Prosthesis type 1.57 0.90–3.30 0.08
Age at operation 1.04 1.00-1.06 0.16
CI, confidence interval.






Hospital mortality (30-day) 2(5.2%) 2(5.7%) NS
Perioperative myocardial infarction 3(7.9%) 3(8.6%) NS
Respiratory failure 2(5.2%) 2(5.7%) NS
Pacemaker placement 1(2.6%) 1(2.9%) NS
Re-exploration for bleeding 2(5.2%) 2(5.7%) NS
Cerebral vascular accident 1(2.6%) 1(2.9%) NS
Sepsis 1(2.6%) 1(2.9%) NS
Deep sternal wound infection 2(5.4%) 2(5.7%) NS
Gastrointestinal complications 1(2.6%) 2(5.7%) <0.05
Length of Intensive care unit stay (days) 3.5 ± 1.0 3.6 ± 1.2 NS
Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant.
Table 5 Follow-up midterm results
Complications Group B(n = 36) Group M(n = 33) P Value
Valve-related 6(16.7%) 11(33.3%) <0.05
Bleeding event 0 2(6.1%) <0.05
Thromboembolism 0 3(9.1%) <0.05
PVE 2(5.6%) 2(6.1%) NS
Valve deterioration 0 0 NS
perivalvular leak 1(2.8%) 1(3.0%) NS
Reoperation 3(8.3%) 3(9.1%) NS
Cardiac death 2 (5.6%) 2(6.1%) NS
Heart failure 1(2.8%) 1(3.0%) NS
Arrhythmia 1(2.8%) 1(3.0%) NS
Non-cardiac death 5(13.9%) 5(15.2%) NS
Malignancy 3(8.3%) 2(6.1%) <0.05
Other 2(5.6%) 3(9.1%) <0.05
Late mortality 7(19.4%) 7(21.2%) NS
Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant. PVE,
prosthetic valve endocarditis.
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in freedom from reoperation between the two groups
(Figure 2; Table 5). In the mechanical valve group, two
patients underwent reoperation for PVE, and one for
perivalvular leak. In the tissue valve group, four patients
underwent reoperation, two for PVE, one for perivalvular
leak and one for structural valve deterioration. The
bioprosthesis valve group had significantly higher freedom
from thromboem-bleeding events (100% versus 77.6 ±
11.0%, p = 0.012), and valve-related morbidity (73.2 ± 10.1%
versus 58.1 ± 10.9%, p = 0.035) in 5 years.Survival analysis
In the subset of dialysis patients receiving hemodialysis,
there was no difference in survival related to the use of
tissue versus mechanical valves. The estimated 5-year
survival rate with bioprosthetic valves was 53.0 ± 17.2%





































Figure 1 Kaplan-Meier freedom from bleeding/thrombotic events.shows Kaplan–Meier survival curves for the entire pa-
tient population stratified by study groups. Kaplan–
Meier survival estimates at 1, 3, and 5 years were 0.971,
0.832, and 0.530 in group B, and 0.967, 0.848, and 0.568
in group M. However, comparison of survival curves be-
tween the two groups revealed no significant difference.
Discussion
Abnormal calcium homeostasis in patients with end-
stage renal failure results in dystrophic calcification.
Valvular and perivalvular involvement in ESRD is most
commonly manifested as mitral annular calcification and
aortic valve calcification [10]. Both mitral and aortic





























































Figure 3 Late-term survival with group B(blue line) versus
group M(green line).
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function [11]. Mitral valve and aortic valve replacement
are indicated for severe symptomatic valve stenosis or
regurgitation [11].
Valve replacement in hemodialysis patients presents a
dilemma to the cardiac surgeon, who must balance the
potential for accelerated prosthetic valve deterioration
against the morbidity of anticoagulation when selecting
a prosthesis [3,5,12]. There is much controversy regard-
ing prosthetic valve selection in patients with ESRD re-
quiring dialysis [6,13,14]. Like other studies [5,9], we
found accelerated calcification of bioprosthesis to be
uncommon in patients on preoperative dialysis. Im-
portantly, Kaplon et al. found no convincing evidence
for accelerated calcification as a major cause of
bioprosthetic valve failure and resultant adverse mor-
bidity and mortality [10]. In fact, the limited sample
size of this study probably does not prevent it from
yielding a meaning conclusion that bioprosthesis could
be a preferable choice for ESRD.
Given the lack of a clinical difference in morbidity
or survival following either mechanical or bioprosthetic
valve replacement, we believe that concern for acceler-
ated calcific bioprosthesis degeneration should not play
a role when choosing a valve for patients on dialysis.
Rather, other variable such as patient age, gender, level
of activity, and presence of infection should dictate
valve selection, and not the diagosis of end-stage renal
failure. We, however, did not observe differences in
preoperative rates of systemic hypertension, smoking
history, diabetes mellitus, endocarditis, or cardiac ar-
rhythmias. In this study, therefore, we investigated the
risk factors of hospital mortality in dialysis-dependent
patients after undergoing cardiac surgery. Univariate
analysis showed that preoperative lower LVEF was im-
portant independent predictors of hospital mortality.In addition, Kaplan-Meier analysis further accentuated
the unacceptably high rates of complications and death
with mechanical valves. Recent reports have demon-
strated the effective use of tissue valves in dialysis pa-
tients, without increased mortality or reoperation
compared to mechanical valves [13,15].
Although life expectancy for patients with ESRD has
gradually improved in the United States, mortality con-
sistently exceeds 25% per year. Four-year survival of
patients on hemodialysis or peritoneal dialysis is ap-
proximately 40% [16]. In the present study, the overall
survival rate of dialysis patients after isolated valve re-
placement of 85.2% at 3 years and 55.9% at 5 years is
clearly better than in previous reports [17]. This might
be due to differences in concomitant procedures and
postoperative anticoagulation therapy for those with
mechanical valves. Although concomitant CABG was
the independent predictors of hospital mortality and sur-
vival in the previous reports [5-7,9], we excluded pa-
tients with CABG because we tried to clarify the long-
term result of isolated valve replacement. Our analysis
showed no significant difference in life expectancy or
rate of reoperation after follow-up 5 years between pa-
tients receiving mechanical or biological prostheses, des-
pite the greater proportion of elderly patients in the
biological prosthesis group.
It is clear that the overall survival of ESRD patients
was poor. In contrast to previous literature [14,18],
differences in survival between patients receiving
bioprostheses or mechanical prostheses were related to
age at operation and not to prosthesis type. In the present
study, we have thus far found no survival difference be-
tween bioprostheses and mechanical prostheses patients.
And age at operation was found to be no different be-
tween the two groups. There was no superiority of free-
dom from all valve-related complications and individual
valve-related complications with mechanical prostheses
or bioprostheses. Bioprostheses should not be contrain-
dicated in ESRD patients given the observed rarity of
accelerated calcification, as well as the poor
intermediate-term survival [18,19].
Chronic dialysis patients tend to have more hemorrhagic
complications. Therefore, dialysis patients undergoing
anticoagulation therapy may be at increased risk of these
complications [5,6]. The target value for anticoagulation
therapy is generally lower in China than in Europe and the
United States: INR is 1.8–2.5 in the case of dialysis patients
in China. This is because minor bleeding complications
(such as nasal bleeding or bleeding from cannulation sites)
often occur among hemodialysis patients receiving warfarin
therapy when their INR exceeds 2.5. During the mean
follow-up of 44 ± 26 months, there were bleeding compli-
cations in 4 of 20 survivors, and no thromboembolic
events occurred. Recently, lower-intensity anticoagulation
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bleeding complications with bileaflet mechanical valves,
without increasing the rate of thromboembolism [17].
The ACC/AHA guidelines were changed in 2006 to
reflect the findings of a series of observational studies
which showed no significant difference in the freedom
from valve-related events including reoperation and late
mortality between patients with dialysis-dependent RF
receiving a mechanical or a biological prosthesis [20]. In
addition to the above findings, a meta-analysis of the
published literature demonstrates no survival difference
following valve replacement with either bioprosthesis or
mechanical prosthesis in patients with ESRD on dialysis.
Some recent studies reported that early structural valve
deterioration was uncommon, even in dialysis patients,
but others showed that it occurred even in new-
generation bioprosthetic valves [21,22]. In fact, these re-
ports also support our current study, which have similar
outcomes than the present paper.
Study limitations
The present study was limited by a lack of randomization,
as are all studies of valve replacement in this category of
population. Furthermore, as no standardized protocols
were used with regard to choice of prosthesis, the data
presented herein are subject to individual surgeon biases.
In addition, our survival analysis is based on a retrospect-
ive study design, and it is possible that selection bias for a
particular choice of valve may have occurred.
Conclusion
In the present study of valve replacement in dialysis pa-
tients, tissue valve structural deterioration was negli-
gible, the need for reoperation was similar with either
mechanical or tissue valves, and there was no difference
in mortality with respect to valve choice. This was most
likely because of the very limited life expectancy of a pa-
tient beginning dialysis. As a result of these findings, it is
recommended that renal failure patients who are on dia-
lysis and require cardiac valve replacement should re-
ceive a bioprosthesis.
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